King Luther Capital Management Corp Raises Stock Position in Prestige Consumer Healthcare Inc. $PBH

King Luther Capital Management Corp raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 150.3% during the 4th quarter, Holdings Channel reports. The firm owned 90,968 shares of the company’s stock after acquiring an additional 54,621 shares during the quarter. King Luther Capital Management Corp’s holdings in Prestige Consumer Healthcare were worth $5,612,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its holdings in Prestige Consumer Healthcare by 4.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock valued at $161,723,000 after purchasing an additional 119,459 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Prestige Consumer Healthcare by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock valued at $98,776,000 after purchasing an additional 21,085 shares during the last quarter. Bank of America Corp DE grew its holdings in Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after purchasing an additional 115,459 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Prestige Consumer Healthcare by 10.2% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after purchasing an additional 60,496 shares during the last quarter. Finally, Raymond James Financial Inc. grew its holdings in Prestige Consumer Healthcare by 15.7% in the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after purchasing an additional 86,373 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PBH. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and an average target price of $70.75.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Stock Up 0.6%

Shares of NYSE:PBH opened at $48.58 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. The stock has a market capitalization of $2.30 billion, a P/E ratio of 12.43, a PEG ratio of 1.55 and a beta of 0.40. The stock has a 50-day simple moving average of $54.89 and a 200-day simple moving average of $60.56. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $87.12.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business’s revenue was down 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).